Results 11 to 20 of about 7,162 (211)

Eculizumab hepatotoxicity in pediatric aHUS [PDF]

Pediatric Nephrology, 2014
Eculizumab is a humanized anti-C5 antibody approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use is increasing in children following reports of its safety and efficacy.We reviewed biochemical and clinical data related to possible drug-induced liver injury in 11 children treated with eculizumab for aHUS in a single center ...
Wesley, Hayes, Sibylle, Tschumi, Simon C, Ling, Janusz, Feber, Michael, Kirschfink, Christoph, Licht   +5 more
openaire   +3 more sources

aHUS: a disorder with many risk factors [PDF]

Blood, 2010
Peer ...
Rodríguez de Córdoba, Santiago, S. Rodriguez de Cordoba   +1 more
openaire   +4 more sources

An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry

Orphanet Journal of Rare Diseases, 2016
Background Patients are becoming increasingly involved in research which can promote innovation through novel ideas, support patient-centred actions, and facilitate drug development.
Len Woodward, Sally Johnson, Johan Vande Walle, Joran Beck, Christoph Gasteyger, Christoph Licht, Gema Ariceta, on behalf of the aHUS Registry SAB   +7 more
doaj   +3 more sources

Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registry [PDF]

Nephrology, 2020
AbstractAimsTo describe the baseline characteristics and treatment of Australian patients diagnosed with atypical haemolytic uraemic syndrome (aHUS) reported to the Global aHUS Registry.MethodsDescriptive analysis of the Australian cohort with aHUS (n = 106) was undertaken for demographics, disease characteristics and prior treatment with eculizumab ...
Jacqueline Soraru, Nicole Isbel, Germaine Wong, Patrick Toby Coates, Murty Mantha, Abu Abraham, Rajiv Juneja, Danny Hsu, Fiona Brown, Bhadran Bose, David Mudge, Robert Carroll, Joshua Kausman, Peter Hughes, Thomas Barbour, Anne Durkan, Peter Mount, Darren Lee, Nicholas Larkins, Dwarakanathan Ranganathan, Wai H. Lim   +20 more
openaire   +6 more sources

Kryptovirus - Ahus [PDF]

, 2023
I moderne tider blir teknologien stadig mer avansert og sofistikert. Denne hektiske utviklingsprosessen fører til økt risiko for å bli angrepet av ondsinnede aktører på nettet. De mest utbredte truslene av denne typen er kryptovirus, etter som at disse har et bredt antall angrepsvektorer tilgjengelig og er i stand til å forårsake betydelig skade på ...
Hiis-Hauge, Sindre, Myhre, Steinar Mjøs, Nessø, Jonas Brumoen, Myrvold, Jørgen Lillehagen   +3 more
openaire   +2 more sources

Clinical case of recurrent aHUS after allogeneic cadaveric kidney transplantation

Вестник трансплантологии и искусственных органов
Introduction. Atypical hemolytic uremic syndrome (aHUS) is a systemic orphan disease that reproduces as an uncontrolled activation of the alternative pathway of the complement system and is expressed as systemic thrombotic microangiopathy (TMA).
S. V. Popov, A. M. Esayan, R. G. Guseynov, I. N. Orlov, E. V. Lomonosova, V. V. Perepelitsa, О. A. Vorobyeva, A. V. Sadovnikova, T. A. Lelyavina   +8 more
doaj   +3 more sources

Application of a scoring system in Japanese patients diagnosed with atypical hemolytic uremic syndrome to assess the relationship between the score and clinical responses to eculizumab

Thrombosis Journal, 2023
Background Atypical hemolytic uremic syndrome (aHUS) is caused by complement dysregulation and is generally diagnosed by exclusion from other disorders of thrombotic microangiopathy (TMA).
Hideo Wada, Hirofumi Teranishi, Akihiko Shimono, Noritoshi Kato, Shoichi Maruyama, Masanori Matsumoto   +5 more
doaj   +1 more source

Anti-factor H antibody and its role in atypical hemolytic uremic syndrome

Frontiers in Immunology, 2022
Atypical hemolytic uremic syndrome (aHUS) an important form of a thrombotic microangiopathy (TMA) that can frequently lead to acute kidney injury (AKI). An important subset of aHUS is the anti-factor H associated aHUS.
Rupesh Raina, Rupesh Raina, Guneive Mangat, Gordon Hong, Raghav Shah, Nikhil Nair, Brian Abboud, Sumedha Bagga, Sidharth Kumar Sethi   +8 more
doaj   +1 more source

Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis

Frontiers in Medicine, 2023
Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by genetic abnormalities, infections, autoimmune diseases, drugs, and malignancies.
Sanober Sadiq, Anatoly Urisman, Onur Cil
doaj   +1 more source

The global aHUS registry: methodology and initial patient characteristics [PDF]

, 2015
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, genetically-mediated systemic disease most often caused by chronic, uncontrolled complement activation that leads to systemic thrombotic microangiopathy (TMA) and renal and other end-organ ...
Johnson, Sally, Masayo Ogawa, Ardissino, Gianluigi, Schaefer, Franz, J. Alexander Cole, Christoph Licht, Cole, J. Alexander, David Cohen, Vande Walle, Johan, Sally Johnson, Christoph Gasteyger, Cole, J Alexander, Larry A. Greenbaum, Ariceta, Gema, Franz Schaefer, Greenbaum, Larry A., Cohen, David, Frémeaux-Bacchi, Véronique, Gianluigi Ardissino, Licht, Christoph, Gasteyger, Christoph, Véronique Frémeaux-Bacchi, Ogawa, Masayo, Gema Ariceta, Greenbaum, Larry A, Johan Vande Walle   +25 more
core   +3 more sources